1) CBCC was founded in 1984 in California as a small cancer clinic and has since expanded to become one of the largest cancer care providers in North America and India, operating multiple centers with over 30 oncologists and providing care and clinical trials to thousands of patients annually.
2) The document provides details on CBCC's centers and operations in the US and India, including locations, services, numbers of patients and clinical trials conducted across various cancer types.
3) CBCC has extensive experience conducting oncology clinical trials, with a focus on trials for breast, lung, ovarian and other cancers, and has participated in trials for many now-approved drugs through their affiliation with UCLA.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
JCI is the world’s leader in health care accreditation and the author and evaluator of the most rigorous international standards in quality and patient safety.
hospital_220_a
With its newly published 5th edition of JCI’s Accreditation Standards for Hospitals, JCI addresses the unique concerns of hospitals and academic medical centers, as well as the challenges of preserving quality care as patients move from inpatient to outpatient and other care providers.
Our unique tracer methodology provides the cornerstone of the JCI on-site survey, serving as a tool for surveyors and health care organizations to evaluate patients and systems in unprecedented depth. JCI separates itself from its competitors with innovations network accreditation, where similar organizations within a single system or larger entity can achieve accreditation efficiently through a single network application.
JCI is committed to keeping pace with the dynamics of global health care while remaining the standard bearer for its universally recognized Gold Seal of Approval®.
Rigorous process for developing international standards
Due to the expertise and scope of its international team, JCI is uniquely positioned to adapt leading global practices to the delivery of local care. Standards are developed and organized around important functions common to all health care organizations. In fact, the functional organization of standards is now the most widely used around the world and has been validated by scientific study, testing, and application.
Standards Advisory Panel
To maintain best practices, JCI turns to its Standards Advisory Panel, comprised of experienced physicians, nurses, administrators, and public-policy experts. The panel guides the development and revision process of the JCI accreditation standards. Panel members are from five major world regions: Latin America and the Caribbean, Asia and the Pacific Rim, the Middle East, Europe, and the United States. The panel’s recommendations are refined based on an international field review of the standards and input from experts and others with unique content knowledge.
Did you know 40-65% of all clinical trials involving FDA-regulated products are being conducted overseas? Time, reduced costs, and easier subject recruitment are the factors that make life science companies to conduct clinical trials overseas.
JCI is the world’s leader in health care accreditation and the author and evaluator of the most rigorous international standards in quality and patient safety.
hospital_220_a
With its newly published 5th edition of JCI’s Accreditation Standards for Hospitals, JCI addresses the unique concerns of hospitals and academic medical centers, as well as the challenges of preserving quality care as patients move from inpatient to outpatient and other care providers.
Our unique tracer methodology provides the cornerstone of the JCI on-site survey, serving as a tool for surveyors and health care organizations to evaluate patients and systems in unprecedented depth. JCI separates itself from its competitors with innovations network accreditation, where similar organizations within a single system or larger entity can achieve accreditation efficiently through a single network application.
JCI is committed to keeping pace with the dynamics of global health care while remaining the standard bearer for its universally recognized Gold Seal of Approval®.
Rigorous process for developing international standards
Due to the expertise and scope of its international team, JCI is uniquely positioned to adapt leading global practices to the delivery of local care. Standards are developed and organized around important functions common to all health care organizations. In fact, the functional organization of standards is now the most widely used around the world and has been validated by scientific study, testing, and application.
Standards Advisory Panel
To maintain best practices, JCI turns to its Standards Advisory Panel, comprised of experienced physicians, nurses, administrators, and public-policy experts. The panel guides the development and revision process of the JCI accreditation standards. Panel members are from five major world regions: Latin America and the Caribbean, Asia and the Pacific Rim, the Middle East, Europe, and the United States. The panel’s recommendations are refined based on an international field review of the standards and input from experts and others with unique content knowledge.
NS1450X - Computerized Systems in Clinical ResearchJudson Chase
I am guest lecturer (paid) at the Boston College William F. Connell School of Nursing (more information at http://www.bc.edu/schools/son/aboutus.html).
Three or four times a year I lecture on the application of Computerized Systems in Clinical Research; this is my course deck from 2014.
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Headquartered in Ukraine Carpathian Research Group LLC is a privately-owned clinical research organization (CRO) supporting broad range of R&D activities for biopharmaceutical and medical device industry across Ukraine and neighbouring countries (including, but not limited to Georgia, Moldova, Turkey, Romania, Bulgaria, Kazakhstan, Uzbekistan and Belarus).
Biopmedical is a Finalist in the mHealth Israel Startup Contest, Biopmedical can identify cancerous cells in epithelial tissue, offering standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines
advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas. The collected data is combined and analyzed using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary transducer will supplement or replace current colposcopy technologies.
Learn more about the commercial context of clinical trials, and how to leverage international networks to provide input into clinical trial designs that will generate value beyond regulatory approval, and provide supporting data to cause the adoption of medical devices.
Most of clinical trials are delayed because recruitment rates do not meet expectations, due to the growing complexity of protocols. North Africa possesses all the features to be an interesting area for numerous clinical trials…..
La plupart des essais cliniques sont annulés, à cause d’un taux de recrutement bas, qui ne satisfait pas les attentes. Cette baisse est due à une croissance de la complexité des projets de recherche. L’Afrique du Nord possède des atouts intéressants favorables pour le déroulement des essais cliniques…..
http://www.e-gcr.com/
TCD MENA was a Main Sponsor of Armed Forces College of Medicine GCP Workshop that was held on 27,28th FEB 2017. Dr. Hanaa Abdel-Maguid (Managing Director - TCD MENA) was an instructor in the GCP Workshop where she presented a session entitled "Sponsor/CRO responsibilties.
TCD MENA CRO is an affiliate of TCD Global headquartered in South Africa, providing end-to-end clinical research services: Regulatory Affairs, Clinical Operations, Project Management, Pharmacovigilance, Data Management, Biostatistics & Medical Writing.
TCD MENA Team has extensive clinical research experience for managing global clinical trials with sites in Egypt and MENA region; also experienced in managing bioequivalence studies accepted by WHO, FDA & EU. The team has worked in different therapeutic areas including Oncology, Hepatology, Internal Medicine, Gynecology, chronic diseases with strong relationships with KOLs across Egypt & MENA region.
TCD MENA Team understands the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions to support R&D objectives in terms of Quality, Time & Cost flexibility.
TCD MENA looks forward to demonstrate its capabilities and commitment to achieve your goals as the start of a long term solid partnership with your respectful organization. TCD Global will remain responsive to global trends and changing customer needs.
Posterior Segment Company Showcase - AGTCHealthegy
Posterior Segment Company Showcase - AGTC at OIS@AAO 2016.
Presenter:
Sue Washer, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This Presentation provides information about the segmentation of oncology market worldwide, Global Oncology market analysis along with Indian Oncology market.
This presentation covers the following information - Indian Government initiatives,Market Challenges,Market Drivers and SWOT Analysis.
NS1450X - Computerized Systems in Clinical ResearchJudson Chase
I am guest lecturer (paid) at the Boston College William F. Connell School of Nursing (more information at http://www.bc.edu/schools/son/aboutus.html).
Three or four times a year I lecture on the application of Computerized Systems in Clinical Research; this is my course deck from 2014.
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Headquartered in Ukraine Carpathian Research Group LLC is a privately-owned clinical research organization (CRO) supporting broad range of R&D activities for biopharmaceutical and medical device industry across Ukraine and neighbouring countries (including, but not limited to Georgia, Moldova, Turkey, Romania, Bulgaria, Kazakhstan, Uzbekistan and Belarus).
Biopmedical is a Finalist in the mHealth Israel Startup Contest, Biopmedical can identify cancerous cells in epithelial tissue, offering standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines
advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas. The collected data is combined and analyzed using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary transducer will supplement or replace current colposcopy technologies.
Learn more about the commercial context of clinical trials, and how to leverage international networks to provide input into clinical trial designs that will generate value beyond regulatory approval, and provide supporting data to cause the adoption of medical devices.
Most of clinical trials are delayed because recruitment rates do not meet expectations, due to the growing complexity of protocols. North Africa possesses all the features to be an interesting area for numerous clinical trials…..
La plupart des essais cliniques sont annulés, à cause d’un taux de recrutement bas, qui ne satisfait pas les attentes. Cette baisse est due à une croissance de la complexité des projets de recherche. L’Afrique du Nord possède des atouts intéressants favorables pour le déroulement des essais cliniques…..
http://www.e-gcr.com/
TCD MENA was a Main Sponsor of Armed Forces College of Medicine GCP Workshop that was held on 27,28th FEB 2017. Dr. Hanaa Abdel-Maguid (Managing Director - TCD MENA) was an instructor in the GCP Workshop where she presented a session entitled "Sponsor/CRO responsibilties.
TCD MENA CRO is an affiliate of TCD Global headquartered in South Africa, providing end-to-end clinical research services: Regulatory Affairs, Clinical Operations, Project Management, Pharmacovigilance, Data Management, Biostatistics & Medical Writing.
TCD MENA Team has extensive clinical research experience for managing global clinical trials with sites in Egypt and MENA region; also experienced in managing bioequivalence studies accepted by WHO, FDA & EU. The team has worked in different therapeutic areas including Oncology, Hepatology, Internal Medicine, Gynecology, chronic diseases with strong relationships with KOLs across Egypt & MENA region.
TCD MENA Team understands the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions to support R&D objectives in terms of Quality, Time & Cost flexibility.
TCD MENA looks forward to demonstrate its capabilities and commitment to achieve your goals as the start of a long term solid partnership with your respectful organization. TCD Global will remain responsive to global trends and changing customer needs.
Posterior Segment Company Showcase - AGTCHealthegy
Posterior Segment Company Showcase - AGTC at OIS@AAO 2016.
Presenter:
Sue Washer, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This Presentation provides information about the segmentation of oncology market worldwide, Global Oncology market analysis along with Indian Oncology market.
This presentation covers the following information - Indian Government initiatives,Market Challenges,Market Drivers and SWOT Analysis.
New science is redefining cancer as a large number of narrowly defined diseases and bringing therapeutic options to an expanded number of patients. With the rapid growth in the oncology treatment landscape, health systems are struggling to adapt and embrace the evolution—including regulatory systems, diagnostic infrastructure, treatment providers and financing mechanisms. These challenges will require urgent attention in light of the strong near-term pipeline of clinically distinctive therapies and new programs that are galvanizing research efforts to change the trajectory for cancer.
Read the full report >> http://imsh.co/2axszmt
অদ্ভুত ২০ কারণেও আপনার প্রেম হয়ে যেতে পারেBeauty World
ভালোবাসা মানেনা কোনো নিয়ম। গবেষকরা বলছেন, ভালোবাসা কিংবা আকর্ষণ মানবদেহে হরমোনের প্রভাবেই হয়ে থাকে। এ লেখায় থাকছে কিছু অদ্ভুত কারণ, যার প্রভাবে ভালোবাসায় পতিত হতে পারেন যে কেউ। এক প্রতিবেদনে বিষয়টি জানিয়েছে বিজনেস ইনসাইডার।
Find eligible patients that fit your protocol faster, identify and secure proven and/or new sites, forecast and measure progress more efficiency. With Covance's proprietary data, your program hits its mark.
HCG, Best Cancer Care Hospital in india. Cancer Treatment, CyberKnife Surgery, Oncology Symptoms, Cancerous Tumors,Breast Cancer Treatment, chemotherapy, Radiation oncology, Medical Oncology, Surgical Oncology.
KPS Clinical Services (KPSCS) is set up by the RAHE Group, with an aim to become one of the India's leading research-based Contract Research Organization (CRO). Our commitment is to improve the quality of human life & to provide world class clinical research services to pharmaceutical, biotechnology, medical device companies, academic and government organizations.
We wish to focus on the prevailing issues in clinical research & give their solutions with a fresh and rational approach. In this endeavor, we have successfully established a team of highly qualified and experienced multi-disciplinary GCP trained personnel. The services provided by KPSCS are knowledge-driven and based on the understanding of the pharmacology and molecular basis of disease. We believe in providing quality services & we prioritize customer relationships.
Real-Time Data. Real-World Impact. Info sheet Covance
Data can help, but simply accessing more data only muddies your decision making. With Covance, you get the right analysis on the right data to empower your studies.
National OncoVenture (NOV) is a Korean government funded oncology drug development program. We are focusing on non-clinical and early stage clinical development of promising oncology drug candidates. These candidates are provided by researchers in academics, research institutes, biotech and pharmaceutical companies. We are co-developing the compounds with the originators through a virtual development model. The majority of the development activities are outsourced to domestic and global CRO/CMOs as well as specialized laboratories throughout the world. During the pre-clinical and clinical development, we aim to improve the value of our candidates by out-licensing our development programs to global pharmaceutical companies who can develop them further for the global market.
National OncoVenture, a system-integrated oncology drug development group, was established in June 2011. NOV is supported and located at the National Cancer Center of Ilsan. NOV is a national research and development project group of the Ministry of Health and Welfare.
Their purpose is to carry out the development of oncology drug candidates that were discovered by domestic pharmaceutical companies or academic institutes. NOV aims to develop the candidates into oncology drugs for the global market by providing significant drug development expertise.
National OncoVenture aspires to break through the bottleneck phenomenon in new drug development. Many academic research institutes and small biotechnology or pharmaceutical companies lack the resources to develop new drugs from the preclinical to clinical stage. We, as the non-originators, lead and support the development with experienced experts through an entire new drug development process.
NOV is the first governmental virtual drug development organization as an independent developer of new oncology drugs in South Korea. We select promising drug candidates from originators and lead joint-development projects of new drug candidates with originators utilized by outside networks. These external networks have the necessary know-how and experiences of new drug developments like CROs, CMOs, and consulting firms.
After completing the non-clinical and early clinical phase development, we license out the candidates or projects to domestic and overseas pharmaceutical companies. The profits are shared with the original candidate providers.
National OncoVenture provides consultations to the originators of drug candidates in need of knowledge, information, and experience for oncology market trends, drug candidates licensing, and various other processes.
2. CBCC Group - Journey at glance
1984 Founded by Dr. Ravi Patel with small cancer clinic of 12,000 Sq. ft.
1990 Expanded into a larger facility with several stations
Began to participate in oncology clinical trials with affiliation to UCLA.1995
1996 Renamed clinic to Comprehensive Blood & Cancer Centre (CBCC).
2007 Opened a new 70,000 sq ft cancer centre becoming the largest centre on west coast,USA.
2008 Inaugurated a brand new centre CBCC CyberKnife® Center.
2011 Acquired an HDXT MRI for expanding diagnosis for Breast Cancer.
2015
Started operation in Gujarat, India.
Started operation in other Indian states Chaatisgadh, Madhyapradesh and Andhra Pradesh.
Started operation in Tamilnadu, India.
2012 Acquired Vigbyor Research India to manage India Operation.
www.cbcc.com
2
3. CBCC Centers in US – Global HQ
Bakersfield, CA Delano, CATempleton, CA
www.cbcc.com
3
4. CBCC USA details
www.cbcc.com
4
Investigators at CBCC USA
Investigator's Name Specialty
Dr Ravi Patel Medical Oncology
Dr Alan Cartmell Medical Oncology
Dr David Kanamori Medical Oncology
Dr Shawn Shambaugh Medical Oncology
Dr Pradip Rustagi Medical Oncology
Dr Kota Chandra Shekar Medical Oncology
Dr Giridhar Gorla Radiation Oncology
Dr Ajay Desai Radiation Oncology
6. CBCC USA details
www.cbcc.com
6
List of Clients:
1. Pfizer
2. Genentech
3. AstraZeneca
4. Lilly
5. Bristol Myers Squib
6. Amgen
7. Bayer
8. ABBVIE
9. Onyx Pharmaceuticals
10. Merck
Studies we have participated that were investigational and now are approved.
Palbociclib
Crizotinib,
Tarceva,
Avastin,
Neupogen,
Procrit,
Herceptin
Perjeta
Kadecyla
Aloxi
Emend
Rituxan
7. UCLA Affiliation
CBCC is part of the UCLA Jonsson Comprehensive Cancer Center's Translational Oncology Research
International (TORI) network. CBCC has collaborated in over 100 clinical trials with UCLA. This partnership
allows CBCC and other leading research institutions and health care providers to offer clinical and
research trials beyond the UCLA campus. All types of cancers are included in these important studies.
What this means to our patients is that they have early access to the latest clinical trials without having to
travel. For a comprehensive list of all our active clinical trials please click here.
www.cbcc.com
7
8. CBCC Hospitals in India
Raipur - Chattisgarh
Indore - Madhyapradesh
Ahmedabad - Gujarat
Trichy - Tamilnadu
Chennai - Tamilnadu
Jadcherla – Andhra Pradesh
www.cbcc.com
8
9. 13/Jan/2016CBCC-VIBGYOR_List of Oncology Sites
9
Apollo CBCC Center Ahmedabad Vamshi CBCC Cancer & General
Hospital, Jadcherla
G Vishwanathan CBCC Cancer
Hospital, Trichy
Dr. Rai CBCC Cancer Center,
Chennai
Sanjeevani CBCC Cancer Hospital,
Raipur
CHL CBCC Cancer Hospital, Indore
CBCC Hospitals in India
10. Infrastructure Details – Site wise/India
10
Center Bed
Strength
No of
Consultants
Core Department Radiology Pathology
Ahmedabad 93 31 Surgical, Medical, Radiation, Hemato
Oncology and Stem Cell Transplant
In House In House
Raipur 70 7 Surgical, Medical, Radiation & Hemato
Oncology
In House In House
Indore 60 8 Surgical, Medical, Radiation & Hemato
Oncology
In House In House
Chennai 50 6 Surgical, Medical, Radiation & Hemato
Oncology
In House Outsourced
Trichy 50 7 Surgical, Medical, Radiation & Hemato
Oncology
In House In House
Jadcherla 70 6 Surgical, Medical, & Hemato Oncology Outsourced Outsourced
11. Annual patient turnover at each site/India
11
Center Surgery Chemo Radiation Total
Ahmedabad 800 4,200 780 5,780
Raipur 480 1,440 480 2,400
Indore 840 2,400 840 4,080
Chennai 600 1,440 600 2,640
Trichy 360 1,080 600 2,040
Jadcherla 450 1200 100 1750
12. Services
Clinical Trial Project Management of Phase II-IV
PK end point studies on patients
Clinical monitoring
Clinical Data Management
Medical Writing and Communication
Pharmacovigilence
Post market Trials of Drugs and Devices
www.cbcc.com
12
13. Oncology Clinical Trial
Capability/Experience
Breast Cancer
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Colon Cancer
Esophageal/Gastric Cancer
www.cbcc.com
13
14. Experience of PK end point studies
PK End point study of liposomal doxorubicin on ovarian Cancer patients: 46 patients enrolled at
12 sites.
PK End point study of liposomal doxorubicin on ovarian Cancer patients: 30 patients enrolled at
08 sites.
PK End point study of Capecitabin on Metastatic Brest Cancer patients: 54 patients enrolled at 10
sites.
PK End point study of Capecitabin on Metastatic Brest Cancer patients: 46 patients enrolled at 08
sites.
PK End point study of Sunitinib on advanced renal cell carcinoma patients: 60 patients enrolled at
10 sites.
PK End point study of Bortezomib on multiple myeloma patients: 30 patients enrolled at 07 sites.
PK End point study of Imatinib on CML patients: 36 patients enrolled at 06 sites.
www.cbcc.com
14
15. Why CBCC for PK end point studies
With extensive setup in India and USA, we recruit patients at our own hospital site and not
dependent on the outside investigator sites for the enrolment.
Common SOP and training system at all our hospital sites in India and USA.
Well equipped sites with infrastructure like Continuous ECG monitoring, Automated
centrifuge , Deep freezer, Pharmacy freezers.
Strong documentation system at all sites to archive study documents which is essential for
regulatory audits at site.
Well trained site staff having experience of managing international regulatory audits.
While recruiting patients for one indication we don’t accept another study with same
indication to complete the total recruitment in the shortest possible time.
CTMS softer with unique sponsor login to present continuous study updates to Sponsor
www.cbcc.com
15
16. Key Differentiator
More than 30 years of rich experience in Clinical trials with core focus on Oncology.
Largest private Cancer Care Provider in North America.
Global outreach to manage complex clinical trials in various locations.
Rich experience of successful trial execution and submission to various regulatory agencies
around the globe.
Very stable top management.
www.cbcc.com
16